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We have previously demonstrated that an improved
affinity TCR generated against NYESO-1 has shown
remarkable efficacy in clinical studies in multiple mye-
loma (NCT01352286). The same TCR is also being
tested in synovial sarcoma (NCT01343043), melanoma
(NCT01350401) and ovarian (NCT01567891) clinical
trials. We will extend these clinical studies to include
hepatocellular carcinoma shortly. In this present study,
we have generated a panel of improved-affinity TCRs
for a widely expressed hepatic carcinoma-specific HLA-
A2-restricted peptide antigen AFP158-166. This TCR
panel demonstrates stepwise increases in affinity from
wildtype to approximately 500-fold greater binding to
cognate antigen. These affinity-enhanced TCRs were
screened for efficacy and specificity by a variety of in
vitro assays, such as interferon gamma ELISpot,
Incucyte™ cytotoxicity assays for visualizing caspase 3/7
activity, Luminex™ multiple cytokine secretion assays
and 3D microtissue models against a variety of hepatocel-
lular carcinoma cell lines and normal primary cell types.
This TCR panel demonstrated a window of activity
whereby moderately increased affinity TCRs showed maxi-
mal response to antigen positive hepatocellular carcinoma
cell lines HepG2, HuH6 and JHH5-A2, whilst showing no
response to primary normal hepatocytes or primary cells
from other organ systems. Greater increases in TCR affi-
nity led to off-target activity, demonstrated as responses to
primary normal target cells as well as antigen positive cell
lines. This data has led to selection of a lead candidate for
full pre-clinical assessment that demonstrates vastly
improved efficacy against hepatocellular carcinoma cell
lines, yet retains specificity by absence of response to pri-
mary normal tissue. This TCR may be suitable for further
clinical studies in hepatocellular carcinoma.
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